Cowen Healthcare Investments
New York, New York, United StatesFounded 2012
Cowen Healthcare Investments (CHI) was a venture capital firm based in New York that invested fiduciary capital in innovative private healthcare companies across biopharma, diagnostics, and digital health. Founded in 2012, the firm was acquired by Blue Owl Capital in 2023 and became Blue Owl Healthcare Opportunities.
53% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Their most common stage is series-b (41% of deals). Average disclosed round size is $97.4M (across 49 rounds with reported amounts).
Portfolio
48
Fund Size
$555.6M
Top Stage
Series B
Last 12 Mo
1
Team
KR
Kevin Raidy
Managing Partner
RS
Robert Sine
Partner/Head Trader
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 SetPoint Medical | Series D | $140M | Sep 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
| FF2G | Series H | $100M | Jan 2024 |
 Aro Biotherapeutics | Series B | $41.5M | Nov 2023 |
 MBrace | Series A | $85M | Nov 2023 |
 MBrace Therapeutics | Series A | $85M | Nov 2023 |
 MapLight Therapeutics | Series C | $225M | Oct 2023 |
| MBrace Therapeutics | Series B | $85M | Jan 2023 |
| MBrace | Series B | $85M | Jan 2023 |
 Nested Therapeutics | Series A | $90M | Oct 2022 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
 Aktis Oncology | Series A | $84M | Aug 2022 |
 Delfi Diagnostics, Inc. | Series B | — | Jul 2022 |
 Delfi | Series B | — | Jul 2022 |
| EElectra Therapeutics | Series B | $84M | Feb 2022 |
| Delfi | Series B | $225M | Jan 2022 |
 Scipher | Series C | — | Jan 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Lycia Therapeutics | Series B | $70M | Sep 2021 |
 Arch Oncology, Inc. | Series C | $105M | Apr 2021 |
 Evox Therapeutics | Series C | $95.4M | Feb 2021 |
| Delfi Diagnostics, Inc. | Series A | $100M | Jan 2021 |
| Delfi | Series A | $100M | Jan 2021 |
| PPersonal Genome Diagnostics (PGDx) | Series C | $103M | Jan 2021 |
 Neuron23 Inc | Series B | $113.5M | Dec 2020 |
Page 1 of 3
Top Co-Investors
OrbiMed18 shared
Redmile Group12 shared
Foresite Capital11 shared
Northpond Ventures11 shared
Samsara BioCapital11 shared
Rock Springs Capital11 shared
Surveyor Capital8 shared
Menlo Ventures8 shared
Windham Capital Partners8 shared
RA Capital Management8 shared
Cormorant Asset Management8 shared
New Enterprise Associates8 shared
T. Rowe Price7 shared
Sofinnova Partners7 shared
Venrock7 shared
Sanofi Ventures6 shared
Illumina Ventures6 shared
AV8 Ventures6 shared
GV6 shared
Eli Lilly and Company6 shared
Last updated: 20 October 2026